Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine Therapy

Poster Pearl: Elacestrant + Abemaciclib for ER+/HER2- Metastatic Breast CancerПодробнее

ELCIN: elacestrant in CDK4/6 inhibitor-naïve ER+/HER2- metastatic breast cancerПодробнее

Update of EMERALD by duration of CDK4/6i in metastatic setting: elacestrant v SoC in ER+/HER2- mBCПодробнее

Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast CancerПодробнее

Elacestrant in ER+/HER2- mBC: Overview of the EMERALD subgroup analysisПодробнее

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBCПодробнее

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy ptsПодробнее

Elacestrant shows improved PFS in patients with ER-positive/HER2-negative metastatic breast cancerПодробнее

Moving the Needle in ER-Positive/HER2-Negative Metastatic Breast Cancer: Exploring SERD Strategie...Подробнее

EMERALD: elacestrant vs. SOC for patients with ER+ HER2- metastatic breast cancerПодробнее

ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancerПодробнее

Elacestrant: A New Weapon Against Advanced Estrogen Receptor-Positive Breast CancerПодробнее

Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metas...Подробнее

ELAINE 1: ESR1 mutations in ctDNA from ER+/HER2- mBC treated with lasofoxifene or fulvestrantПодробнее

ER-Positive Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019Подробнее

What's New for the Patient With ER+/HER2- MBC Progressing on CDK 4/6 Inhibitor Therapy? Expert Pe...Подробнее

Breast Cancer Breakthroughs: Dr. Donald McDonnell explains how elacestrant was discovered in his labПодробнее

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR+/HER2- metastatic breas...Подробнее

Treating ER+/HER2-low metastatic breast cancer, 2L and beyondПодробнее